Safety and efficacy of crizanlizumab in adolescents with sickle cell disease (SCD): Initial data from the phase II, multicenter, open-label Solace-Kids trial

Authors
Category Primary study
JournalHemaSphere
Year 2022
This article has no abstract
Epistemonikos ID: 8cd59feba1d0e4645f87da5f850fce6f51a5ade5
First added on: Feb 13, 2025